Key Takeaways
- Clinical Bottom Line
- The Evolution of Transluminal Tissue Acquisition
Clinical Bottom Line
| Sampling Modality | Needle Architecture | Histological Yield |
|---|---|---|
| FNA (Fine Needle Aspiration) | Standard beveled tip; relies on intense vacuum suction. | Yields primarily single cells (Cytology); requires an on-site pathologist (ROSE). |
| FNB (Fine Needle Biopsy) | Franzen or Fork-tip core needle; physically cuts tissue. | Yields intact architectural core tissue (Histology); highly accurate for neuroendocrine tumors. |
The Evolution of Transluminal Tissue Acquisition
Endoscopic Ultrasound (EUS) is no longer a purely diagnostic modality; it is the definitive method for securing tissue from pancreatic masses and malignant lymph nodes. Historically, EUS relied heavily on Fine Needle Aspiration (FNA), aggressively jabbing a thin needle into the tumor while applying heavy syringe suction to literally rip single cells free.
The Shift to Core Histology
Because FNA yields a bloody smear of isolated cells, it requires a cytopathologist sitting inside the procedure room (Rapid On-Site Evaluation, ROSE) to physically look at the slides under a microscope in real-time to confirm adequacy. In 2026, the universal adoption of novel Fine Needle Biopsy (FNB) needles—featuring complex geometries like the “Franseen” tri-prong crown—has fundamentally altered the EUS workflow. The FNB needle acts like a microscopic cookie cutter, shearing off intact, solid cores of tissue. This produces massive histological samples that preserve tumor architecture, allowing for advanced genomic sequencing and virtually eliminating the expensive logistical requirement for on-site ROSE pathology.
Clinical guidelines summarized by the Gastroscholar Research Team. Last updated: 2026. This article is intended for physicians.
